Naya Biosciences, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
INVO Fertility, Inc. (IVF) filed its Q2 2026 Form 10-Q, showing revenue growth driven by clinic acquisitions, but also highlighting ongoing liquidity concerns and material weaknesses in internal controls.
INVO Fertility, Inc. reported a significant net loss for the nine months ended September 30, 2025, driven by the divestiture of NAYA Therapeutics and related impairment charges, despite revenue growth in its core fertility clinic services.
INVO Fertility, Inc. divests majority stake in NAYA Therapeutics to refocus on core fertility business, reporting significant net losses and ongoing liquidity challenges in its latest quarterly filing.
INVO Fertility reports its Q1 2025 financial results while strategically refocusing on its fertility business and planning the divestiture of its majority stake in NAYA Therapeutics.
10-Q: NAYA Biosciences Reports Third Quarter 2024 Results, Revenue Growth Driven by Clinic Acquisitions
NAYA Biosciences' third quarter 2024 results show significant revenue growth primarily driven by the acquisition of the Wisconsin Fertility Institute.
NAYA Biosciences has amended its Q2 2024 report to restate previous financial statements due to an error in lease accounting, while also reporting a net loss for the quarter.
INVO Bioscience saw a significant revenue increase in the second quarter of 2024, primarily due to the acquisition of the Wisconsin Fertility Institute.
INVO Bioscience's first quarter revenue significantly increased due to the acquisition of Wisconsin Fertility Institute, while the company continues to navigate financial challenges.